NeuroMetrix (NURO) Competitors $4.55 +0.19 (+4.36%) Closing price 05/1/2025Extended Trading$4.55 0.00 (0.00%) As of 05/1/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NURO vs. DXR, COCH, TMDIF, POCI, MDAI, BDMD, NMTC, PTHL, DRIO, and PYPDShould you be buying NeuroMetrix stock or one of its competitors? The main competitors of NeuroMetrix include Daxor (DXR), Envoy Medical (COCH), Titan Medical (TMDIF), Precision Optics (POCI), Spectral AI (MDAI), Baird Medical Investment (BDMD), NeuroOne Medical Technologies (NMTC), Pheton Holdings Ltd Class A Ordinary Shares (PTHL), DarioHealth (DRIO), and PolyPid (PYPD). These companies are all part of the "medical equipment" industry. NeuroMetrix vs. Daxor Envoy Medical Titan Medical Precision Optics Spectral AI Baird Medical Investment NeuroOne Medical Technologies Pheton Holdings Ltd Class A Ordinary Shares DarioHealth PolyPid Daxor (NASDAQ:DXR) and NeuroMetrix (NASDAQ:NURO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations. Do analysts rate DXR or NURO? Daxor presently has a consensus target price of $25.00, indicating a potential upside of 222.16%. Given Daxor's stronger consensus rating and higher probable upside, analysts clearly believe Daxor is more favorable than NeuroMetrix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00NeuroMetrix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer DXR or NURO? NeuroMetrix received 282 more outperform votes than Daxor when rated by MarketBeat users. However, 100.00% of users gave Daxor an outperform vote while only 56.13% of users gave NeuroMetrix an outperform vote. CompanyUnderperformOutperformDaxorOutperform Votes2100.00% Underperform VotesNo VotesNeuroMetrixOutperform Votes28456.13% Underperform Votes22243.87% Which has preferable valuation & earnings, DXR or NURO? Daxor has higher earnings, but lower revenue than NeuroMetrix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDaxor$2.13M17.61N/AN/AN/ANeuroMetrix$3.03M3.09-$6.53M-$4.59-0.99 Does the media refer more to DXR or NURO? In the previous week, NeuroMetrix had 1 more articles in the media than Daxor. MarketBeat recorded 1 mentions for NeuroMetrix and 0 mentions for Daxor. Daxor's average media sentiment score of 0.00 equaled NeuroMetrix'saverage media sentiment score. Company Overall Sentiment Daxor Neutral NeuroMetrix Neutral Do insiders & institutionals believe in DXR or NURO? 1.3% of Daxor shares are held by institutional investors. Comparatively, 19.4% of NeuroMetrix shares are held by institutional investors. 59.0% of Daxor shares are held by insiders. Comparatively, 7.3% of NeuroMetrix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, DXR or NURO? Daxor has a beta of -0.21, indicating that its share price is 121% less volatile than the S&P 500. Comparatively, NeuroMetrix has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500. Is DXR or NURO more profitable? Daxor has a net margin of 0.00% compared to NeuroMetrix's net margin of -203.71%. Daxor's return on equity of 0.00% beat NeuroMetrix's return on equity.Company Net Margins Return on Equity Return on Assets DaxorN/A N/A N/A NeuroMetrix -203.71%-42.56%-39.26% SummaryDaxor beats NeuroMetrix on 9 of the 14 factors compared between the two stocks. Get NeuroMetrix News Delivered to You Automatically Sign up to receive the latest news and ratings for NURO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NURO vs. The Competition Export to ExcelMetricNeuroMetrixSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.37M$4.49B$5.37B$8.39BDividend YieldN/A43.63%5.22%4.10%P/E Ratio-0.9929.4326.8419.71Price / Sales3.0967.72392.34117.39Price / CashN/A51.0838.2534.62Price / Book0.356.236.794.50Net Income-$6.53M$68.16M$3.23B$248.18M7 Day PerformanceN/A18.33%4.07%1.14%1 Month Performance5.32%23.04%12.52%15.20%1 Year Performance19.11%20.61%16.83%6.56% NeuroMetrix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NURONeuroMetrix0.1295 of 5 stars$4.55+4.4%N/A+14.3%$9.37M$3.03M-0.9920High Trading VolumeDXRDaxor3.8084 of 5 stars$7.68+0.3%$25.00+225.5%-21.5%$37.15M$2.13M0.0037Gap UpCOCHEnvoy Medical1.7404 of 5 stars$1.70+1.2%$9.13+436.8%-46.9%$36.26M$212,000.00-1.2334TMDIFTitan MedicalN/A$0.31-9.6%N/A+771.4%$34.83M$17.63M-0.2450POCIPrecision Optics0.6792 of 5 stars$4.48-0.9%N/A-32.6%$34.34M$18.68M-7.0080Earnings ReportGap DownMDAISpectral AI2.9053 of 5 stars$1.35-2.2%$4.75+251.9%-26.1%$34.18M$29.58M-2.0883Analyst RevisionBDMDBaird Medical InvestmentN/A$5.12+0.6%N/AN/A$33.71M$33.05M0.00N/ANMTCNeuroOne Medical Technologies1.7303 of 5 stars$0.66-0.6%$1.45+119.3%-40.8%$32.94M$5.75M-2.5420Gap UpPTHLPheton Holdings Ltd Class A Ordinary SharesN/A$4.85-12.5%N/AN/A$31.92M$448,196.000.0011DRIODarioHealth1.65 of 5 stars$0.66flat$2.00+203.0%-60.8%$29.01M$27.04M-0.70200News CoverageEarnings ReportAnalyst ForecastPYPDPolyPid2.1493 of 5 stars$2.81+2.6%$11.33+303.3%-34.5%$28.64MN/A-0.5780Earnings ReportHigh Trading Volume Related Companies and Tools Related Companies Daxor Competitors Envoy Medical Competitors Titan Medical Competitors Precision Optics Competitors Spectral AI Competitors Baird Medical Investment Competitors NeuroOne Medical Technologies Competitors Pheton Holdings Ltd Class A Ordinary Shares Competitors DarioHealth Competitors PolyPid Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NURO) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroMetrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroMetrix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NURO Stock Free NURO Stock Alerts